Back to results
US 2009/0023694 A1Published application
Contraceptive
AssigneeGrüNenthal GmbH
InventorsGeorg Schramm, Christa Kneip, Johannes Schneider
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGrüNenthal GmbH
InventorsGeorg Schramm, Christa Kneip, Johannes Schneider
Estimating the term…
The present invention relates to an administration form for hormonal contraception consisting of a particular number of hormone-containing daily units, comprising a hormone combination consisting of at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen component, and at least one metabolite of chlormadinone acetate selected from the group comprising 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-2-one (3β-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and/or 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one as the gestagen component for the uninterrupted, daily, oral administration of the hormone-containing daily units, optionally in combination with 7 to 3 hormone-free daily units.
Administration form for hormonal contraception comprising at least one hormone-containing daily units, comprising a hormone combination comprising at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen components, and at least one metabolite of chlormadinone acetate selected from the group comprising 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and/or 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one as the gestagen component for uninterrupted, daily, oral administration of the hormone-containing daily units, optionally in combination with 7 to 3 hormone-free daily units.
A method for monophase hormonal contraception comprising administering a hormone combination of ethinyl oestradiol and/or oestradiol as the oestrogen component and at least one metabolite of chlormadinone acetate selected from the group comprising 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and/or 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one as the gestagen component for at least 21 days, optionally in combination with 7 to 3 hormone-free daily units.
Dependencies are inferred from the claim text.